
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
The American Journal of Managed Care
over 26 years ago
Ischemic Stroke: Acute Management and Secondary Preventionover 26 years ago
Is Cost-Effectiveness Modeling Useful?





